Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance IGT and Type 2 Diabetes T2D in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome PCOS

NCT03122041 is registered in ClinicalTrials.gov with University Medical Centre Ljubljana as lead sponsor.

NCT NCT03122041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03122041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance IGT and Type 2 Diabetes T2D in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome PCOS
Lead sponsor
University Medical Centre Ljubljana
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2016
Completion date
November 30, 2016
Enrollment
30 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pcos